LifeVantage 将来の成長
Future 基準チェック /06
LifeVantageの収益と利益はそれぞれ年間6.4%と10.7%減少すると予測されていますが、EPS は年間10.8% 減少すると予測されています。
主要情報
-10.7%
収益成長率
-10.81%
EPS成長率
| Personal Products 収益成長 | 28.3% |
| 収益成長率 | -6.4% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 13 May 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • Jun 24
LFVN: Downgrade And Softer Guidance Will Set Up Portugal Expansion Upside
Analysts have trimmed their price target on LifeVantage to $7.00, reflecting a modestly higher discount rate and slightly adjusted P/E assumptions following the latest downgrade in Street research. What’s in the News for LifeVantage LifeVantage updated earnings guidance for the fiscal year ending June 30, 2026, indicating that fiscal 2026 revenue is expected to be close to the lower end of the previously issued guidance range.ナラティブの更新 • Jun 08
LFVN: Downgrade And Softer Guidance Will Limit Portugal Expansion Support
Analysts have reduced their fair value estimate for LifeVantage after a recent downgrade in Street research coverage, reflecting a slightly lower discount rate and modestly adjusted expectations for revenue trends, profit margins, and future P/E multiples. What's in the News LifeVantage updated guidance for the fiscal year ending June 30, 2026, and now expects revenue to be close to the lower end of its previously issued range.ナラティブの更新 • May 17
LFVN: Reset Expectations And Portugal Expansion Will Support Future Upside Potential
Analysts cut their price target on LifeVantage from $8 to $7, reflecting a lower fair value estimate, softer profit margin assumptions, and a higher future P/E, following the recent downgrade highlighted in Street research. Analyst Commentary Recent Street commentary points to a more cautious stance on LifeVantage, with the lower price target tied to reassessed earnings power and valuation assumptions following the downgrade.ナラティブの更新 • May 01
LFVN: Share Repurchases And Reset Expectations Will Support Future Upside Potential
Analysts have trimmed their price target on LifeVantage by $7, reflecting updated views on the company’s fair value and earnings power following recent research. Analyst Commentary Analysts cutting the target price by $7 signals a reset in expectations around what they see as a fair value for LifeVantage, given recent research on the company’s earnings power and execution risks.ナラティブの更新 • Apr 17
LFVN: Share Repurchases And Portugal Expansion Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, revenue trends, profit margins, and expected future P/E multiples. Analyst Commentary Analysts link the lower price target to updated views on discount rates, revenue trends, profit margins, and expected future P/E multiples, which together affect how much investors may be willing to pay for LifeVantage shares.ナラティブの更新 • Apr 02
LFVN: Share Repurchases And Margin Discipline Will Support Future Upside Potential
Analysts have reduced their price target on LifeVantage by $7, citing updated assumptions around discount rates, long term revenue trends, profit margins, and future P/E expectations. Analyst Commentary Analysts cutting the price target by $7 are updating their framework for discount rates, long term revenue trends, profit margins, and future P/E expectations.ナラティブの更新 • Mar 19
LFVN: Share Repurchases And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their $7.00 price target on LifeVantage, citing updated fair value, discount rate, revenue, margin, and future P/E assumptions that now point to a more measured risk and return profile for the stock. Analyst Commentary Analysts cutting their $7.00 price target are largely reacting to updated views on fair value, discount rate, revenue, margins, and future P/E assumptions, which together frame a more balanced outlook for LifeVantage.ナラティブの更新 • Mar 05
LFVN: Buybacks And Margin Improvement Will Support Future Upside Potential
Narrative Update on LifeVantage Analysts have lowered their price target on LifeVantage by $7, citing updated assumptions for the discount rate, revenue trajectory, profit margin and future P/E, which together indicate a more cautious valuation framework. Analyst Commentary Analysts describe the lower price target as a reset of expectations rather than a change in the core story, anchoring their work in updated views on discount rate, revenue trajectory, profit margin and future P/E.ナラティブの更新 • Feb 18
LFVN: Higher Future P/E And Buybacks Will Support Confident Upside Potential
Analysts have reduced their price target on LifeVantage from $14.50 to $8.00, citing updated assumptions for revenue trends, profit margins, and a slightly adjusted discount rate, even as they apply a somewhat higher future P/E multiple. Analyst Commentary Analysts cutting the price target to $8.00 are recalibrating how they see LifeVantage balancing execution risk with potential upside in its valuation.分析記事 • Feb 06
Investors Give LifeVantage Corporation (NASDAQ:LFVN) Shares A 26% Hiding
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 26% in the last...ナラティブの更新 • Feb 04
LFVN: Gut Health Research Progress Will Support Confident Upside Potential
Analysts are keeping their price target for LifeVantage steady at US$14.50, indicating only very small adjustments in their discount rate and long term assumptions such as revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News LifeVantage announced new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration across four gut cell types (Key Developments).ナラティブの更新 • Jan 21
LFVN: Gut Study Advances And Guidance Confidence Will Support Future Upside Potential
Analysts have kept their price target for LifeVantage unchanged at $14.50, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E, rather than a shift in their overall view of the stock. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, showing strong biological activity in cellular pathways tied to gut regulation, repair, and restoration across four gut cell types, with all 14 analyzed peptides and proteins moving in the intended direction in a controlled, third party study (Key Developments).ナラティブの更新 • Jan 07
LFVN: Gut Study Progress Will Drive Future Upside Potential
Analysts have slightly adjusted their price target for LifeVantage to $14.50, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin, and future P/E used in their valuation models. What's in the News LifeVantage reported new in vitro study results for its proprietary P84 formula, with all 14 analyzed gut-related peptides and proteins moving in the desired direction in a controlled, third-party study across four gut cell types (Key Developments).ナラティブの更新 • Dec 22
LFVN: Future Gut Health Research And Buybacks Will Drive Upside
Analysts have modestly raised their price target on LifeVantage to 14.50 dollars from 14.50 dollars, citing largely unchanged expectations for fair value, discount rate, revenue growth, profit margins, and future valuation multiples that together reinforce a stable outlook for the shares. What's in the News New in vitro study of LifeVantage's P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several biomarkers increasing well above the 20 to 30 percent threshold typically considered meaningful in controlled cellular research (Key Developments) Key P84 results included a 1,087 percent increase in gastrin releasing peptide, a 116 percent increase in trefoil factor 3 for gut lining repair, and a 100 percent increase in vasoactive intestinal peptide that helps calm overactive areas of the gut (Key Developments) LifeVantage plans next phase research using mRNA sequencing to study P84 in combination with its Protandim Nrf2 Synergizer and MindBody GLP 1 System formulas, deepening the scientific backing for its gut and cellular activation portfolio (Key Developments) LifeVantage reported it has repurchased a cumulative 5,068,960 shares, or 37.65 percent of its outstanding stock, for 43.27 million dollars under a buyback program initiated in 2017, including 44,364 shares in the most recent quarter (Key Developments) The company reiterated fiscal 2026 guidance, expecting full year revenue between 225 million and 240 million dollars and forecasting second half revenue to exceed the first half, supported by MindBody product seasonality and the LoveBiome acquisition (Key Developments) Valuation Changes Fair Value Estimate: unchanged at 14.50 dollars per share, indicating no material shift in the intrinsic value assessment.ナラティブの更新 • Dec 08
LFVN: Future Index Inclusion Will Drive Upside Potential
Analysts have modestly raised their price target on LifeVantage to approximately $14.50 per share, reflecting slightly updated assumptions for discount rates, long term revenue growth, and profitability, while maintaining a broadly unchanged fair value outlook. What's in the News New in vitro study of LifeVantage’s proprietary P84 gut health formula showed strong biological activity across 14 key gut peptides and proteins, with several markers, including GRP, TFF3, VIP, and OXM, demonstrating notably large increases in levels, supporting the scientific rationale behind the product portfolio expansion (company study announcement).ナラティブの更新 • Nov 24
LFVN: Share Repurchases and New Index Addition Will Drive Value
LifeVantage Analyst Price Target Revised Downward Amid Softer Growth Expectations Analysts have lowered their price target for LifeVantage from $18.00 to $14.50. They cite reduced projections for revenue growth and profit margins as key factors in their updated assessment.分析記事 • Nov 14
Lacklustre Performance Is Driving LifeVantage Corporation's (NASDAQ:LFVN) 28% Price Drop
Unfortunately for some shareholders, the LifeVantage Corporation ( NASDAQ:LFVN ) share price has dived 28% in the last...分析記事 • Nov 04
We Ran A Stock Scan For Earnings Growth And LifeVantage (NASDAQ:LFVN) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Sep 30
It's Down 25% But LifeVantage Corporation (NASDAQ:LFVN) Could Be Riskier Than It Looks
LifeVantage Corporation ( NASDAQ:LFVN ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • Sep 05
LifeVantage (NASDAQ:LFVN) Will Pay A Dividend Of $0.045
The board of LifeVantage Corporation ( NASDAQ:LFVN ) has announced that it will pay a dividend on the 16th of...Seeking Alpha • Jul 21
The LifeVantage Advantage: High Retention, High Returns
Summary LifeVantage leads in nutrigenomics, focusing on how nutrition impacts gene expression for optimal health. LifeVantage projections indicate a strong 26.6% EPS CAGR through 2027, driven by high-margin products, cost controls, and a shift toward long-term wellness-focused consultant strategies. The MindBody GLP-1 System now accounts for most of LFVN’s growth, with 85% of new users on monthly subscriptions, creating a reliable and recurring revenue stream. Shares trade at a discounted 15.6x forward P/E, below the staples sector median and peers like Nature’s Sunshine, offering valuation upside, alongside dividend yield and liquidity strength. Risks include heavy reliance on one product and retention uncertainty, as subscription fatigue, or competitive GLP-1 alternatives could weaken revenue durability and challenge the bullish case. Read the full article on Seeking Alpha分析記事 • May 13
Shareholders Can Be Confident That LifeVantage's (NASDAQ:LFVN) Earnings Are High Quality
When companies post strong earnings, the stock generally performs well, just like LifeVantage Corporation's...分析記事 • May 02
What You Can Learn From LifeVantage Corporation's (NASDAQ:LFVN) P/E After Its 26% Share Price Crash
To the annoyance of some shareholders, LifeVantage Corporation ( NASDAQ:LFVN ) shares are down a considerable 26% in...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 6/30/2028 | 165 | 4 | N/A | N/A | 1 |
| 6/30/2027 | 178 | 5 | 11 | 16 | 3 |
| 6/30/2026 | 184 | 5 | 7 | 15 | 3 |
| 3/31/2026 | 195 | 6 | 4 | 7 | N/A |
| 12/31/2025 | 210 | 8 | 2 | 4 | N/A |
| 9/30/2025 | 229 | 10 | 9 | 10 | N/A |
| 6/30/2025 | 229 | 10 | 11 | 12 | N/A |
| 3/31/2025 | 222 | 9 | 12 | 13 | N/A |
| 12/31/2024 | 212 | 7 | 13 | 14 | N/A |
| 9/30/2024 | 196 | 4 | 5 | 7 | N/A |
| 6/30/2024 | 200 | 3 | 10 | 12 | N/A |
| 3/31/2024 | 205 | 4 | 11 | 13 | N/A |
| 12/31/2023 | 211 | 3 | 11 | 14 | N/A |
| 9/30/2023 | 213 | 3 | 9 | 13 | N/A |
| 6/30/2023 | 213 | 3 | 4 | 7 | N/A |
| 3/31/2023 | 210 | -1 | 3 | 6 | N/A |
| 12/31/2022 | 206 | -1 | 1 | 3 | N/A |
| 9/30/2022 | 205 | 0 | 4 | 6 | N/A |
| 6/30/2022 | 206 | 3 | 6 | 8 | N/A |
| 3/31/2022 | 210 | 9 | 12 | 14 | N/A |
| 12/31/2021 | 212 | 10 | 13 | 16 | N/A |
| 9/30/2021 | 219 | 14 | 15 | 18 | N/A |
| 6/30/2021 | 220 | 13 | 13 | 16 | N/A |
| 3/31/2021 | 225 | 12 | 13 | 17 | N/A |
| 12/31/2020 | 229 | 12 | 15 | 17 | N/A |
| 9/30/2020 | 232 | 12 | 18 | 21 | N/A |
| 6/30/2020 | 233 | 12 | 16 | 18 | N/A |
| 3/31/2020 | 230 | 12 | 13 | 16 | N/A |
| 12/31/2019 | 230 | 12 | N/A | 17 | N/A |
| 9/30/2019 | 227 | 8 | N/A | 12 | N/A |
| 6/30/2019 | 226 | 7 | N/A | 18 | N/A |
| 3/31/2019 | 224 | 7 | N/A | 16 | N/A |
| 12/31/2018 | 218 | 6 | N/A | 16 | N/A |
| 9/30/2018 | 210 | 6 | N/A | 13 | N/A |
| 6/30/2018 | 203 | 6 | N/A | 13 | N/A |
| 3/31/2018 | 200 | 3 | N/A | 10 | N/A |
| 12/31/2017 | 194 | 1 | N/A | 6 | N/A |
| 9/30/2017 | 194 | 1 | N/A | 6 | N/A |
| 6/30/2017 | 199 | 2 | N/A | 7 | N/A |
| 3/31/2017 | 202 | 4 | N/A | 4 | N/A |
| 12/31/2016 | 213 | 5 | N/A | 3 | N/A |
| 9/30/2016 | 216 | 6 | N/A | 6 | N/A |
| 6/30/2016 | 207 | 6 | N/A | 6 | N/A |
| 3/31/2016 | 199 | 4 | N/A | 10 | N/A |
| 12/31/2015 | 188 | 3 | N/A | 14 | N/A |
| 9/30/2015 | 184 | 3 | N/A | 11 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: LFVNの収益は今後 3 年間で減少すると予測されています (年間-10.7% )。
収益対市場: LFVNの収益は今後 3 年間で減少すると予測されています (年間-10.7% )。
高成長収益: LFVNの収益は今後 3 年間で減少すると予測されています。
収益対市場: LFVNの収益は今後 3 年間で減少すると予想されています (年間-6.4% )。
高い収益成長: LFVNの収益は今後 3 年間で減少すると予測されています (年間-6.4% )。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: LFVNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/03 02:14 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/06/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
LifeVantage Corporation 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Ilya Zubkov | Freedom Broker |
| Mitchell Pinheiro | Imperial Capital |
| Ryan Meyers | Lake Street Capital Markets, LLC |